EH 2_2015

A R E V O L U T I O N A R Y C O M B I N A T I O N O F ©CarestreamHealth,Inc,2014 Introducing Touch Ultrasound* From a world leader in imaging comes a revolution in ultrasound: The CARESTREAM Touch Ultrasound System. With a configurable All-Touch control panel like nothing the industry has ever seen, Touch Ultrasound offers a new level of intuitive operation, innovative productivity tools and a powerful processor that provides both efficiency and advanced image quality. The combination of touch and sound has arrived. From a world leader in imaging comes a revolution in ultrasound: The CARESTREAM Touch Ultrasound System. With a configurable All-Touch control panel like nothing the industry has ever seen, innovative productivity tools and a powerful processor that carestream.com/touch *Not Available for Commercial Sale www.healthcare-in-europe.com 23RADIOLOGY A new powerful partnership Driving proton and carbon therapy worldwide A global collaboration to expand access to advanced particle ther- apy worldwide was agreed this April between Belgian firm IBA (Ion Beam Applications S.A.) and the Toshiba Corporation. In Japan, Toshiba Medical Systems Corporation will distribute Proteus ONE, IBA’s compact single-room proton therapy solution, and IBA will be the agent for Toshiba’s Carbon Therapy Solutions outside Japan. The two companies will col- laborate on activities such as cus- tomer education for both systems. Additionally, the collaboration will enable both organisations to gear up their Operation and Maintenance (O&M) services. Proton and carbon therapy Proton Therapy is considered an advanced and targeted cancer radio- therapy treatment due to its supe- rior dose distribution and fewer side effects, IBA reports. ‘Protons depos- it the majority of their effective energy within a precisely controlled range, directly within the tumour, sparing healthy surrounding tissue. Higher doses can be delivered to the tumour without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. ‘Carbon ions not only have similar physical characteristics as protons, they have also a higher radiobio- logical effect compared to pho- ton and proton, which could lead to shorter treatment courses and improved patient outcomes.’ Olivier Legrain, Chief Executive Officer of IBA, which produces universal full-scale proton therapy centres as well as compact, single room systems, sees the partnership as important to take both thera- pies worldwide. ‘Carbon ion therapy is particularly suitable for treating radio-resistant tumours and allows for dose escalation, which is rec- ommended in a number of clinical applications.’ According to Satoshi Tsunakawa, Chief Executive Officer of Healthcare Company, Toshiba Corporation, pro- ton and carbon therapies are ‘… among the most exciting technologi- cal advancements in the treatment of cancer.’ Quoting the firm’s motto “Committed to People, Committed to the Future” he added that the collaboration ‘will give both our Proteus ONE, IBA’s compact single-room proton therapy solution companies an enhanced set of tools to provide the best cancer treatment technologies’. PICTURECREDIT:SourceIBA

EH 2_2015

Pages Overview